Skip to content

The effect of BMI in the first trimester on fetal heart morphology and function in pregnant women with gestational diabetes mellitus with good blood glucose control

The effect of BMI in the first trimester on fetal heart morphology and function in pregnant women with gestational diabetes mellitus with good blood glucose control

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125877
Enrollment
Unknown
Registered
2026-06-01
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gestational diabetes

Interventions

Double negative control group:none
Simply overweight/obese group:none
GDM group alone:none
Double exposure group:none

Sponsors

Shengjing Hospital Affiliated to China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Ultrasound measurements of various fetal growth indicators were consistent with gestational age, with no known recognizable genetic or chromosomal abnormalities; 2. All participants underwent an oral glucose tolerance test (OGTT) screening for gestational diabetes mellitus (GDM). The diagnostic criteria were based on the revised Chinese standards of August 2014. GDM was diagnosed if the OGTT results conducted between 24 and 28 weeks of gestation met any one or more of the following criteria: (1) Fasting blood glucose >= 5.1 mmol/L, (2) 1-hour blood glucose >= 10.0 mmol/L, (3) 2-hour blood glucose >= 8.5 mmol/L. For confirmed GDM cases, good blood glucose control was defined as HbA1c < 6.0%; 3. Gestational age of 26–30 weeks; 4. All enrolled cases had clear images, with the target positioned at the center of the image, a clean and unobstructed background, clearly showing the fetal four-chamber heart view.

Exclusion criteria

Exclusion criteria: 1. Multiple pregnancy; 2. Maternal history of smoking, drinking, hypertension, pregestational diabetes (PGDM), heart and liver disease, combined with preeclampsia, thyroid dysfunction, autoimmune diseases and other chronic diseases; 3. Fetal heart structure abnormalities (such as congenital heart disease, etc.), arrhythmias or chromosomal abnormalities. 4. Fetal growth restriction (FGR) or macrosomia.

Design outcomes

Primary

MeasureTime frame
global sphericity index;left ventricular ejection fraction;left ventricular septal wall strain;left ventricular global longitudinal strain;

Countries

China

Contacts

Public ContactYu Wang

Shengjing Hospital Affiliated to China Medical University

sea_186@126.com+86 189 4025 7832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026